ARTICLE SUMMARY:
The diabetes device arena is has seen a number of new product approvals and launches recently, some of which have the potential to dramatically change the patient care paradigm. Two new devices in particular have attracted substantial attention: Medtronic’s 670G, the first artificial pancreas (AP) system to reach commercialization, now in limited launch in the US; and Abbott’s newly FDA-approved FreeStyle Libre Flash glucose monitoring system, a low-cost, on-demand wearable glucose sensor system.
The diabetes device arena is a unique space in the medtech field—more consumer-driven than other device markets—and it is an area that is seeing an explosion of new devices and high-tech disease-management solutions aimed at empowering patients, improving their quality of life, and positively impacting outcomes in the process.
